MGI/SuperGen’s Dacogen Is "Approvable" Pending Transfusion Data Analysis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MGI/SuperGen’s myelodysplastic syndromes therapy Dacogen (decitabine) is "approvable" at FDA pending submission of additional analysis of transfusion data